203 related articles for article (PubMed ID: 11999550)
1. Angiogenic and lymphangiogenic molecules in hematological malignancies.
Orpana A; Salven P
Leuk Lymphoma; 2002 Feb; 43(2):219-24. PubMed ID: 11999550
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in lymphoproliferative disorders.
Salven P
Acta Haematol; 2001; 106(4):184-9. PubMed ID: 11815716
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):316-21. PubMed ID: 12607599
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies.
List AF
Oncologist; 2001; 6 Suppl 5():24-31. PubMed ID: 11700389
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study.
Sipos B; Weber D; Ungefroren H; Kalthoff H; Zühlsdorff A; Luther C; Török V; Klöppel G
Int J Cancer; 2002 Dec; 102(6):592-600. PubMed ID: 12448000
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Rofstad EK; Halsør EF
Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
[TBL] [Abstract][Full Text] [Related]
7. New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter?
de Bont ES; Neefjes VM; Rosati S; Vellenga E; Kamps WA
Leuk Lymphoma; 2002 Oct; 43(10):1901-9. PubMed ID: 12481883
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
Zachary I
IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611
[TBL] [Abstract][Full Text] [Related]
9. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Giles FJ
Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
11. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
12. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
Kim MH
J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor as a target opportunity in hematological malignancies.
Bellamy WT
Curr Opin Oncol; 2002 Nov; 14(6):649-56. PubMed ID: 12409656
[TBL] [Abstract][Full Text] [Related]
14. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.
Nagy JA; Vasile E; Feng D; Sundberg C; Brown LF; Detmar MJ; Lawitts JA; Benjamin L; Tan X; Manseau EJ; Dvorak AM; Dvorak HF
J Exp Med; 2002 Dec; 196(11):1497-506. PubMed ID: 12461084
[TBL] [Abstract][Full Text] [Related]
15. The molecular perspective: VEGF and angiogenesis.
Goodsell DS
Stem Cells; 2003; 21(1):118-9. PubMed ID: 12529559
[No Abstract] [Full Text] [Related]
16. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test.
Rogala E; Skopińska-Rózewska E; Sommer E; Pastewka K; Chorostowska-Wynimko J; Sokolnicka I; Kazoń M
Anticancer Res; 2001; 21(6B):4259-63. PubMed ID: 11908679
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in acute and chronic leukemias.
Dickson DJ; Shami PJ
Leuk Lymphoma; 2001; 42(5):847-53. PubMed ID: 11697639
[TBL] [Abstract][Full Text] [Related]
19. The biology of VEGF and its receptors.
Ferrara N; Gerber HP; LeCouter J
Nat Med; 2003 Jun; 9(6):669-76. PubMed ID: 12778165
[TBL] [Abstract][Full Text] [Related]
20. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Relf M; LeJeune S; Scott PA; Fox S; Smith K; Leek R; Moghaddam A; Whitehouse R; Bicknell R; Harris AL
Cancer Res; 1997 Mar; 57(5):963-9. PubMed ID: 9041202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
